The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.

The major will use funds from the sale of its male hypogonadism product to invest in future innovation, which is likely to focus on high-risk high-reward cell and gene drug candidates.